Hasan S, et al. - Given that randomized studies have shown a survival benefit for consolidative thoracic radiotherapy (TRT) in extensive stage (ES) small cell lung cancer (SCLC), researchers analyzed the radiation dose and optimal selection criteria in this investigation. They examined 3,280 stage IV SCLC treated with double-agent chemotherapy and TRT within the National Cancer Data Base (NCDB) and assessed the differences in selection patterns and survival outcomes for subjects who received at least 45 Gy of TRT and those who received < 45 Gy. The data presented showed a dose of at least 45 Gy compared to less than 45 Gy was an independent predictor of survival. The study findings suggested that in select extensive stage SCLC patients dose escalated thoracic radiotherapy might be considered.